ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 141,46
-0,67%
Dow Jones
39 834,07
0,07%
DAX
18 726,76
-0,21%
Brent Oil
82,565
-1,16%
Bitcoin
69 802,09
-2,31%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) Actualités

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
De:
Trier par:
 Showing the most relevant articles for your search:LSE:HCM
DateHeureSourceTitreSymboleSociété
17/05/202418h58Alliance NewsAlliance NewsIN BRIEF: Hutchmed China Simon To leaves role, succeeded by Dan EldarLSE:HCMHutchmed (china) Limited
17/05/202416h00RNS Regulatory NewsHutchmed (China) Limited Retirement of Chairman and new Chairman appointedLSE:HCMHutchmed (china) Limited
17/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Data to be Presented at EHA2024 CongressLSE:HCMHutchmed (china) Limited
14/05/202415h33Alliance NewsAlliance NewsHutchmed announces trials of HMPL-306 and Surufatinib cancer therapiesLSE:HCMHutchmed (china) Limited
14/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Registrational Phase III TrialLSE:HCMHutchmed (china) Limited
14/05/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Initiates Phase II/III Trial with HengruiLSE:HCMHutchmed (china) Limited
10/05/202414h00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
08/05/202410h30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
26/04/202417h09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
26/04/202414h30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
22/04/202410h30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
08/04/202410h30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
05/04/202410h30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
02/04/202411h32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
02/04/202408h00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
28/03/202412h08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
28/03/202408h00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
22/03/202411h09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
22/03/202408h16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
22/03/202408h00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
14/03/202410h00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
05/03/202409h30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
28/02/202418h31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
28/02/202413h45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
28/02/202412h30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
07/02/202410h50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
07/02/202408h00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
02/02/202410h52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
02/02/202409h37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
01/02/202409h30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Dernières Valeurs Consultées

EU
VIV
Vivendi
EU
RNO
Renault
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
EU
ORA
Orange
EU
GLE
Societe Generale
EU
EN
Bouygues
EU
VK
Vallourec
NYSE
JPM
JP Morgan Chase
EU
MC
Lvmh Moet Hennessy Louis...
EU
CAP
Capgemini
EU
SGO
Cie de SaintGobain
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés